title: Subjective assessment of a new moisturizing mouthwash for the symptomatic management of dry mouth.
abstract: OBJECTIVE
  A randomized clinical trial and consumer usage test were conducted to evaluate the acceptability and benefits of OASIS Moisturizing Mouthwash in subjects experiencing symptoms of dry mouth.
  
  
  METHODS
  Study 1: A randomized, double blind, two-period crossover clinical trial was conducted in 49 subjects to evaluate OASIS Moisturizing Mouthwash and an experimental mouthwash formulation. Following a three-day acclimatization phase, subjects used both products at home for three days. Each treatment phase was separated by a three-day washout period. Study 2: Subjects participated in a one- to two-week home usage consumer test using OASIS Moisturizing Mouthwash, after which they completed a 52-question online survey exploring sensory benefits and resultant quality of life attributes of the product.
  
  
  RESULTS
  Study 1: A total of 46 adults with a mean age of 64 years completed the study. On average, subjects used the test products three times per day. OASIS Moisturizing Mouthwash was found to be beneficial in managing dry mouth, and was well-liked by the study population, as evidenced by a statistically significant improvement over subjects' normal remedies for managing dry mouth for strength of flavor, taste, freshening breath, immediate and long lasting lubrication, and moisturization. Both products were well-tolerated. Study 2: Three-hundred and twenty-three subjects completed a one- to two-week consumer home usage test followed by an online questionnaire. On a five-point scale, over 80% of respondents perceived the OASIS Moisturizing Mouthwash as "excellent" or "very good" on sensory attributes such as taste and texture, and 70-80% gave the product an "excellent" or "very good" rating on benefit attributes.
  
  
  CONCLUSIONS
  These studies showed that OASIS Moisturizing Mouthwash was beneficial in managing dry mouth, and was well-liked by the study population.
authors.affiliation: GlaxoSmithKline, Weybridge, UK. Soha.C.Shirodaria@gsk.com
authors.forename: Soha
authors.initials: S
authors.lastname: Shirodaria
authors.forename: Tony
authors.initials: T
authors.lastname: Kilbourn
authors.forename: Andrew
authors.initials: A
authors.lastname: Butler
authors.forename: Stephanie
authors.initials: S
authors.lastname: Middleton
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009067:Mouthwashes / Q000737:chemistry / Q000627:therapeutic use*; D017060:Patient Satisfaction; D011758:Pyrroles / Q000737:chemistry / Q000627:therapeutic use*; D013997:Time Factors; D014753:Vinyl Compounds / Q000737:chemistry / Q000627:therapeutic use*; D014987:Xerostomia / Q000523:psychology / Q000628:therapy*
chemical_list: D009067:Mouthwashes; D011758:Pyrroles; D014753:Vinyl Compounds; C118676:poly(divinyl-co-N-vinylpyrrolidinone)